Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
epinephrine + vasopressin + methylprednisolone
- Development stage
- Unknown
- Lead developer
- Korea University Guro Hospital
- Modality
- Peptides, Small Molecules
- Administration
- Intravenous
01
Overview
Experimental Group 3 refers to a specific triple-combination therapeutic regimen consisting of epinephrine, vasopressin, and the corticosteroid methylprednisolone. This combination is being investigated by Korea University Guro Hospital in the VSE Study for the treatment of out-of-hospital cardiac arrest (OHCA). The rationale for this combination is to leverage the potent vasopressor effects of epinephrine and vasopressin to maintain coronary perfusion pressure during cardiopulmonary resuscitation (CPR), while utilizing methylprednisolone to mitigate the systemic inflammatory response and potential adrenal insufficiency associated with post-cardiac arrest syndrome. The study aims to determine if this combination improves the rate of return of spontaneous circulation (ROSC) and long-term neurological outcomes compared to standard epinephrine-only treatment.
- Other names
- VSE combinationVasopressin-Steroid-Epinephrine combination
02
Targets
ADRB2 (β2)AVPR2 (Arginine vasopressin V2 receptor)AVPR1A (Arginine vasopressin receptor 1A)ADRA2A (α2A)ADRA1A (α1A)GR (Glucocorticoid receptor)ADRB1 (β1)
Beyond the preview
Go deeper on epinephrine + vasopressin + methylprednisolone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on epinephrine + vasopressin + methylprednisolone.